Shenzhen - Delayed Quote CNY

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ)

13.49 +0.61 (+4.74%)

At close: October 30 at 3:04:04 PM GMT+8

Chart Range Bar

Loading chart for 300122.SZ

Previous Close 12.88
Open 12.30
Bid 13.47 x --
Ask 13.49 x --
Day's Range 12.88 - 13.75
52 Week Range 11.07 - 22.18
Volume 52,223,418
Avg. Volume 36,035,837
Market Cap (intraday) 32.292B
Beta (5Y Monthly) 0.44
PE Ratio (TTM) --
EPS (TTM) -5.88
Earnings Date --
Forward Dividend & Yield -- (0.00%)
Ex-Dividend Date Dec 25, 2024
1y Target Est 15.73

Chongqing Zhifei Biological Products Co., Ltd., a biopharmaceutical company, engages in the research and development, production, sale, and distribution of vaccine and biological products in China. The company offers recombinant COVID-19 vaccine; recombinant mycobacterium tuberculosis fusion protein products; group A and C meningococcal polysaccharide vaccine; ACYW135 meningococcal polysaccharide vaccine; Haemophilus Influenza type B conjugate vaccine; mycobacterium injection under the Vaccae brand; and meningococcal group A and C conjugate vaccine. It also provides cold storage, refrigerated vehicles, and cold roll boxes; and customs clearance and registration of imported vaccines. The company was founded in 2002 and is based in Chongqing, China.

www.zhifeishengwu.com

6,292

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300122.SZ

28.51%

SSE Composite Index (000001.SS)

9.32%

1-Year Return

300122.SZ

32.48%

SSE Composite Index (000001.SS)

9.73%

3-Year Return

300122.SZ

77.56%

SSE Composite Index (000001.SS)

19.11%

5-Year Return

300122.SZ

85.40%

SSE Composite Index (000001.SS)

1.46%

Earnings Per Share (GAAP)

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q3 FY26

Revenue 2.51B

Earnings --

Profit Margin 0.00%

FY25

FY26

-10B

-5B

-1000.0%

-800.0%

-600.0%

-400.0%

-200.0%

0.0%

Analyst Price Targets

12.20 Low

15.73 Average

13.49 Current

19.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

-179.28%
Return on Assets (ttm)

-28.39%
Return on Equity (ttm)

-62.70%
Revenue (ttm)

7.85B
Net Income Avi to Common (ttm)

-14.08B
Diluted EPS (ttm)

-5.88

Balance Sheet and Cash Flow

Total Cash (mrq)

2.32B
Total Debt/Equity (mrq)

56.14%
Levered Free Cash Flow (ttm)

11.3B

300015.SZ Aier Eye Hospital Group Co., Ltd.

8.52 +3.65%

000661.SZ Changchun High-Tech Industry (Group) Co., Ltd.

69.69 -2.30%

300760.SZ Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

181.75 +1.54%

300142.SZ Walvax Biotechnology Co., Ltd.

10.89 -5.39%

300347.SZ Hangzhou Tigermed Consulting Co., Ltd

49.67 +3.07%

U.S. markets closed

Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ)

4.82%

-3.51%

-10.96%

-28.51%

-32.48%

-86.17%

93.79%

Chongqing Zhifei Biological Products Co., Ltd. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share (GAAP)

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch